202 related articles for article (PubMed ID: 35034160)
1. Prognostic significance of CTNNB1 mutation in early stage endometrial carcinoma: a systematic review and meta-analysis.
Travaglino A; Raffone A; Raimondo D; Reppuccia S; Ruggiero A; Arena A; Casadio P; Zullo F; Insabato L; Seracchioli R; Mollo A
Arch Gynecol Obstet; 2022 Aug; 306(2):423-431. PubMed ID: 35034160
[TBL] [Abstract][Full Text] [Related]
2. Clinicopathological features and prognostic significance of CTNNB1 mutation in low-grade, early-stage endometrial endometrioid carcinoma.
Ruz-Caracuel I; López-Janeiro Á; Heredia-Soto V; Ramón-Patino JL; Yébenes L; Berjón A; Hernández A; Gallego A; Ruiz P; Redondo A; Peláez-García A; Mendiola M; Hardisson D
Virchows Arch; 2021 Dec; 479(6):1167-1176. PubMed ID: 34420090
[TBL] [Abstract][Full Text] [Related]
3. CTNNB1 (beta-catenin) mutation identifies low grade, early stage endometrial cancer patients at increased risk of recurrence.
Kurnit KC; Kim GN; Fellman BM; Urbauer DL; Mills GB; Zhang W; Broaddus RR
Mod Pathol; 2017 Jul; 30(7):1032-1041. PubMed ID: 28281553
[TBL] [Abstract][Full Text] [Related]
4. CTNNB1 Mutations and Aberrant β-Catenin Expression in Ovarian Endometrioid Carcinoma: Correlation With Patient Outcome.
Zyla RE; Olkhov-Mitsel E; Amemiya Y; Bassiouny D; Seth A; Djordjevic B; Nofech-Mozes S; Parra-Herran C
Am J Surg Pathol; 2021 Jan; 45(1):68-76. PubMed ID: 32769429
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant treatment in early-stage endometrial cancer: context-dependent impact of somatic
Kurnit KC; Fellman BM; Mills GB; Bowser JL; Xie S; Broaddus RR
Int J Gynecol Cancer; 2022 Jul; 32(7):869-874. PubMed ID: 35483739
[TBL] [Abstract][Full Text] [Related]
6. Clinicopathologic and Immunohistochemical Correlates of CTNNB1 Mutated Endometrial Endometrioid Carcinoma.
Costigan DC; Dong F; Nucci MR; Howitt BE
Int J Gynecol Pathol; 2020 Mar; 39(2):119-127. PubMed ID: 30702464
[TBL] [Abstract][Full Text] [Related]
7. Molecular markers in recurrent stage I, grade 1 endometrioid endometrial cancers.
Moroney MR; Davies KD; Wilberger AC; Sheeder J; Post MD; Berning AA; Fisher C; Lefkowits C; Guntupalli SR; Behbakht K; Corr BR
Gynecol Oncol; 2019 Jun; 153(3):517-520. PubMed ID: 30910249
[TBL] [Abstract][Full Text] [Related]
8. Ovarian and endometrial endometrioid carcinomas have distinct CTNNB1 and PTEN mutation profiles.
McConechy MK; Ding J; Senz J; Yang W; Melnyk N; Tone AA; Prentice LM; Wiegand KC; McAlpine JN; Shah SP; Lee CH; Goodfellow PJ; Gilks CB; Huntsman DG
Mod Pathol; 2014 Jan; 27(1):128-34. PubMed ID: 23765252
[TBL] [Abstract][Full Text] [Related]
9. Clinicopathologic Evaluation of CTNNB1 Mutations in High-Intermediate Risk Endometrial Endometrioid Carcinoma.
Haag JG; Wolsky RJ; Moroney MR; Sheren J; Sheeder J; Bitler BG; Corr BR
Int J Gynecol Pathol; 2023 Jan; 42(1):43-53. PubMed ID: 35283443
[TBL] [Abstract][Full Text] [Related]
10. Clinical impact of genetic alterations of CTNNB1 in patients with grade 3 endometrial endometrioid carcinoma.
Kobayashi Kato M; Asami Y; Takayanagi D; Matsuda M; Shimada Y; Hiranuma K; Kuno I; Komatsu M; Hamamoto R; Matsumoto K; Ishikawa M; Kohno T; Kato T; Shiraishi K; Yoshida H
Cancer Sci; 2022 May; 113(5):1712-1721. PubMed ID: 35278272
[TBL] [Abstract][Full Text] [Related]
11. Nuclear β-catenin localization and mutation of the CTNNB1 gene: a context-dependent association.
Kim G; Kurnit KC; Djordjevic B; Singh C; Munsell MF; Wang WL; Lazar AJ; Zhang W; Broaddus R
Mod Pathol; 2018 Oct; 31(10):1553-1559. PubMed ID: 29795437
[TBL] [Abstract][Full Text] [Related]
12. TCGA molecular subgroups of endometrial carcinoma in ovarian endometrioid carcinoma: A quantitative systematic review.
D'Alessandris N; Travaglino A; Santoro A; Arciuolo D; Scaglione G; Raffone A; Inzani F; Zannoni GF
Gynecol Oncol; 2021 Nov; 163(2):427-432. PubMed ID: 34446267
[TBL] [Abstract][Full Text] [Related]
13. Clinical significance of CTNNB1 mutation and Wnt pathway activation in endometrioid endometrial carcinoma.
Liu Y; Patel L; Mills GB; Lu KH; Sood AK; Ding L; Kucherlapati R; Mardis ER; Levine DA; Shmulevich I; Broaddus RR; Zhang W
J Natl Cancer Inst; 2014 Sep; 106(9):. PubMed ID: 25214561
[TBL] [Abstract][Full Text] [Related]
14. Improved Risk Assessment by Integrating Molecular and Clinicopathological Factors in Early-stage Endometrial Cancer-Combined Analysis of the PORTEC Cohorts.
Stelloo E; Nout RA; Osse EM; Jürgenliemk-Schulz IJ; Jobsen JJ; Lutgens LC; van der Steen-Banasik EM; Nijman HW; Putter H; Bosse T; Creutzberg CL; Smit VT
Clin Cancer Res; 2016 Aug; 22(16):4215-24. PubMed ID: 27006490
[TBL] [Abstract][Full Text] [Related]
15. Estrogen/Progesterone Receptor Loss, CTNNB1 and KRAS Mutations Are Associated With Local Recurrence or Distant Metastasis in Low-Grade Endometrial Endometrioid Carcinoma.
Chibbar R; Foerstner S; Suresh J; Chibbar R; Piche A; Kundapur D; Kanthan R; Kundapur V; Lee CH; Agrawal A; Lai R
Appl Immunohistochem Mol Morphol; 2023 Mar; 31(3):181-188. PubMed ID: 36695555
[TBL] [Abstract][Full Text] [Related]
16. CTNNB1 p.D32A (c.95A > C) somatic mutation in stage I grade 1 endometrioid endometrial carcinoma with lung metastasis: a case report.
Zhong L; Jiang W; RutieYin ; Liu H; Song L
BMC Med Genomics; 2023 Jun; 16(1):137. PubMed ID: 37328769
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical Nuclear Expression of β-Catenin as a Surrogate of CTNNB1 Exon 3 Mutation in Endometrial Cancer.
Travaglino A; Raffone A; Saccone G; De Luca C; Mollo A; Mascolo M; De Placido G; Insabato L; Zullo F
Am J Clin Pathol; 2019 Apr; 151(5):529-538. PubMed ID: 30715091
[TBL] [Abstract][Full Text] [Related]
18. Aberrant nuclear β-catenin distribution does not prognosticate recurrences of endometrioid endometrial cancers - A retrospective single-institutional study.
Beshar I; Moon AS; Darji H; Liu C; Jennings MT; Dorigo O; Litkouhi B; Diver EJ; Karam AK; Howitt BE; Renz M
Gynecol Oncol; 2023 Dec; 179():85-90. PubMed ID: 37944330
[TBL] [Abstract][Full Text] [Related]
19. Identification of a Gene Panel for Endometrioid Endometrial Cancer: a Possible Prognostic Value?
Malentacchi F; Turrini I; Sorbi F; Projetto E; Castiglione F; Vergoni F; Amunni G; Fambrini M; Petraglia F; Noci I; Pillozzi S
Reprod Sci; 2020 Feb; 27(2):592-598. PubMed ID: 32046431
[TBL] [Abstract][Full Text] [Related]
20. Corded and Hyalinized Endometrioid Adenocarcinoma (CHEC) of the Uterine Corpus are Characterized by CTNNB1 Mutations and Can Show Adverse Clinical Outcomes.
Ladwig NR; Umetsu SE; Zaloudek C; Rabban J; Garg K
Int J Gynecol Pathol; 2021 Mar; 40(2):103-115. PubMed ID: 32909971
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]